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In this study we wanted to investigate the role of the transcriptional factor HNF4A in the 
normal and diseased status of kidney. We proceeded with this objective by studying the 
expression of HNF4A in a range of kidney diseases.  Diabetic nephropathy, Acute renal 
rejection, IgA nephropathy, Minimal change kidney disease, Acute tubular injury, 
Interstitial fibrosis and tubular atrophy (IFTA) were included in this study. We found by 
immunostaining that HNF4A is upregulated in all disease conditions except IFTA. 
HNF4A is known to regulate a wide range of genes involved in metabolic pathways, cell 
proliferation etc. Hence HNF4A upregulation could be responsible for the complex 
molecular changes that occur during these disease conditions contributing to the severity 
of the disease.  
           After having shown that HNF4A is upregulated in a range of disease conditions, 
we wanted to focus our attention on diabetic nephropathy. We were interested in studying 
which target genes of HNF4A could be upregulated in diabetic nephropathy. We thought 
that Acyl Coenzyme A dehydrogenase Very long chain (ACADVL) could be a target of 
HNF4A as it has been previously shown that ACADVL is upregulated in HEK293 cells 
overexpressing HNF4A (Lucas et al., 2005). ACADVL is involved in the oxidation of 
fatty acids. We showed that ACADVL is upregulated in a type 2 diabetic mouse model 
and in human diabetic nephropathy.  This could lead to increased fatty acid oxidation in 
diabetes which can eventually lead to increased ketoacidosis, which is a serious 
complication in diabetes. 
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          After having shown that ACADVL is upregulated together with HNF4A in 
diabetes, we wanted to show that ACADVL is a direct target of HNF4A. For this purpose 
we investigated the genomic sequence of ACADVL for HNF4A response elements. 
Three possible response elements were analyzed. By dual luciferase reporter assay we 
showed that only one of the response elements for HNF4A is biologically active.  This 
novel HNF4A response element is situated +370bp downstream of the translation start 
site of ACADVL.  
      We also sought to investigate the mechanism by which HNF4A and its target genes  
are upregulated in diabetes. We found by luciferase reporter assay that hyperglycemia in 
diabetes activates HNF4A promoter and target genes. Furthermore, we showed that 
HNF4A over expression increases high glucose induced cell death. HEK293 cells stably 
over expressing HNF4A was seen to have reduced cell survival under high glucose 
conditions compared to the control cells. This can have important implications for 
diabetic nephropathy where there is a high glucose environment present. Hence increased 
HNF4A expression in diabetic nephropathy would lead to reduced cell survival.  
       HNF4A is known to play a role in cellular and metabolic processes. Hence the 
upregulation of HNF4A can have important consequences for these disease conditions. 
For example in diabetes, increase in HNF4A levels could lead to upregulation of 
gluconeogenic enzymes such as Phosphoenol Pyruvate Carboxy Kinase (PEPCK). This 
could lead to increased gluconeogenesis in diabetes, which can lead to worsening of the 
diabetic condition.  
     Our finding that HNF4A and some of its target genes such as ACADVL is 
upregulated in the kidney diseases offers some possibilities for therapeutic intervention to 
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alleviate the disease condition.  We hypothesize that some metabolic and cellular changes 
in these disease conditions are due to HNF4A upregulation. Therefore if we could 
suppress HNF4A expression or use a potent inhibitor against HNF4A, it would be 
possible to lessen the severity of the disease. We intend to carry out in vitro screening for 












































1.1   Kidney in normal physiology and disease 
 
Kidney is one of the most important homeostatic organs in the body. They are 
responsible for regulation of electrolytes, acid base balance and blood pressure. Kidneys 
excrete waste byproducts such as urea and ammonium (Stuart et al., 2000). They are also 
responsible for reabsorption of glucose and amino acids. Additionally they play a role in 
producing hormones such as vitamin D, rennin and erythropoietin. Since the kidneys play 
such an essential role in maintaining homeostasis, there can be serious consequences if 
their function is impaired. When kidney function is impaired there would be build up of 
waste products and excess fluid. Eventually all organs would be affected and lead to 
multiple organ failure. 
 
1.2 Kidney disease 
Kidney disease and kidney failure are reaching pandemic proportions in Singapore and 
the world (Vathsala A., 2007).  The incidence of kidney disease is projected to increase in 
the near future, this could have significant economic and social impact.  Most kidney 
diseases affect the nephrons, causing them to lose their filtration capacity. Damage to 
kidneys can occur quickly as a result of injury or poisoning. However, most kidney 






1.2.1 Diabetic nephropathy     
   Diabetes is one of the most common diseases that can affect the function of the kidneys 
(Vathsala A., 2007).  Diabetic nephropathy can be seen in patients with chronic 
uncontrolled diabetes, usually in less than 15 years from the onset. It is the leading cause 
of death in young diabetic patients (50 to 70 years old) (Fioretto et al., 2010). In diabetes 
the high blood glucose can cause damage to the kidneys. The damage occurs over many 
years or decades, eventually leading to kidney failure. Keeping blood glucose levels low 
can prevent or delay kidney damage. The earliest signs of diabetic nephropathy is the 




1.2.2 Ischemic/hypertensive nephropathy 
In ischemic/hypertensive nephropathy renal, arterial stenosis leads to prolonged renal 
ischemia (Vesna et al., 2010). The ischemia in turn causes loss of renal function. 
Hypertension is a characteristic of ischemic nephropathy. Hypertension can also affect 
the kidneys by damaging the small blood vessels in the nephrons.   
 
1.2.3 Acute kidney rejection 
Acute kidney rejection was also included in our study. Acute rejection usually begins 
around 1 week after transplantation (Lahdou et al., 2010). The risk of acute rejection is 
highest during the first three months after transplantation. Acute rejection occurs in 
around 10-30% of all kidney transplants (Schold et al., 2010).   
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1.2.4  IgA nephropathy 
IgA nephropathy is the most common glomerulonephritis in the world (Segelmark et al., 
2010). IgA nephropathy is characterized by deposition of the IgA antibody in the 
glomerulus . This leads to inflammation of the glomeruli thus affecting its function. In 
IgA nephropathy 20-30 % of the cases progress to chronic renal failure during a period of 
20 years (Segelmark et al., 2010). 
 
1.2.5  Minimal change disease 
Minimal change disease is a kidney disease which causes nephrotic syndrome. It usually 
affects children. It is the most common cause of nephrotic syndrome in children under 10 
years (Mathieson et al., 2003). It can also occur in adults, although to a lower degree. The 
main symptoms are proteinurea and edema. One of the unique characteristics of minimal 
change disease is the absence of pathological changes under light microscopy (Cameron 
et al., 1987). However under electron microscopy, characteristic changes can be seen. 
There is loss of podocyte foot processes and vacuolation. The reasons for incidence of 
minimal change disease is not known.  
 
1.2.6  Renal intersitial fibrosis and tubular atrophy 
When the supporting connective tissue in the renal parenchyma exceeds 5%  of the cortex 
it can be said that interstitial fibrosis is present (Serón  et al., 2009). Interstitial fibrosis 
usually occurs together with tubular atrophy, where tubules have thick redundant 
basement membranes. Tubules are considered to have atrophied when their tubular 
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diameter has reduced more than 50% compared to other normal tubules (Serón  et al., 
2009). 
 
1.2.7 Acute tubular necrosis 
Acute tubular necrosis (ATN) is characterized by the death of tubular cells. ATN can 
eventually lead to acute renal failure. ATN is one of the most common causes of acute 
renal failure (John et al., 2009). ATN can be diagnosed by the presence of dead epithelial 
cells during urinalysis. ATN can either be toxic or ischemic in nature. Toxic ATN can be 
caused by hemoglobin or myoglobin or medications such as antibiotics (Andreoli  et al., 
2009). 
 
1.3 Potential role of the transcriptional factor Hepatocyte Nuclear Factor 4A in 
kidney disease 
   Understanding the molecular changes that occur in the kidney diseases would allow us 
to develop better treatments and diagnostic methods. Probably the function and 
expression of many proteins are changed in these disease conditions. Transcriptional 
factors are an attractive target since they are known to regulate many other target proteins. 
Hence if we could modulate the expression or activity of the transcriptional factors we 
might be able to affect the outcome of the disease. 
        Several transcriptional factors are known to be expressed in the kidney.  In our study 
we chose to focus on Hepatocyte nuclear factor 4A (HNF4A) which is expressed in the 




1.4  Regulation of Hepatocyte nuclear factor 4A(HNF4A) 
 
HNF4A belong to the NR2A1 group of ligand dependent transcriptional factors (Sladek 
et al., 1990). Since a definitive ligand has not been identified it is still considered as an 
orphan receptor. It was considered to be constitutively active by being constantly bound 
by fatty acids (Sladek et al., 2002) . However recent findings have identified linoleic acid 
as an endogenous ligand of HNF4A. It was shown that Linoleic acid binds to HNF4A 
reversibly (Yuan et al., 2009).  The ligand binding domain of HNF4A adopts a alpha 
helical sandwich fold, similar to other nuclear receptors (Duda et al., 2004).  HNF4A is 
also regulated by interaction with other co-activator proteins. For example Evi et al 
(2000) has shown that CREB-binding protein (CBP) can acetylate HNF4A, increasing its 
transcriptional activity. PGC-1 alpha is also one of the important co-activators of HNF4A. 
It had been shown that PGC-1 alpha acts synergistically with HNF4A and stimulates 
glucose 6 phosphatase promoter (Xufen et al., 20007 
 
HNF4A like other transcription factors bind to response elements in the DNA sequence. 
Most HNF4A binding sites can be seen as direct repeats of AGGTCA with a spacing of 
one nucleotide (Sladek et al., 1990). HNF4A also binds to DR2 elements with a spacing 
of 2 nucleotides but not to repeats with 0, 3, 4 nucleotide spacings (Jiang et al., 1997). 
There could be significant variation from the consensus AGGTCA, however most true 










Around 55 distinct targets genes have been identified for HNF4A. Most of these target 
genes have more than one HNF4A binding sites, hence the total number of HNF4A 
binding sites is around 74 (Ellrott  et al., 2002). The target genes belong to several 
categories such as nutrient transport, metabolism, blood maintenance, immune function, 
liver differentiation and growth factors (Battle et al., 2006). The most well characterized 
target genes are involved in lipid transport (eg:Apolipoprotein genes) and glucose 
metabolism ( eg: liver Pyruvate Kinase , Phosphoenol Pyruvate Carboxy Kinase ) (Wang 
et al., 1999). 
       HNF4A has been found to regulate the expression of erythropoietin which is 
involved in blood maintenance (Makita et al., 2001).  HNF4A was found to regulate 
erythropoietin during embryonic development in the liver.  It was reported that HNF4A 
binds to DR2 element in the erythropoietin promoter after e11.5 and regulate its 
expression (Makita et al., 2001). It has been shown that HNF4A is competes with retinoic 
acid receptors for occupancy of the DR2 element in the Epo gene promoter (Makita et al., 
2001). HNF4A is also known to regulate Angiotensinogen and the clotting factors, Factor 
VII, Factor VIII and Factor IX (Yanai et al., 1999). As stated previously HNF4A 
regulates genes involved in immune function. For example HNF4A is known to regulate 
macrophage stimulating protein and factor B which are involved in immune regulation 
(Atsuhisa et al., 1998). The other major group of genes regulated by HNF4A is the liver 
differentiation genes and growth factors.  HNF4A is known to regulate other hepatocyte 
nuclear factors such as HNF1A and HNF6.   Due to its importance in liver differentiation, 
liver specific knockout of HNF4A severely affects liver architecture and function 
(Xioling et al., 2007). Almost all known target genes are expressed in the liver and some 
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in the pancreas. Although there are high levels of HNF4A in the kidney only a few 
targets are known to be expressed in the kidney. 
 
1.6  HNF4A expression in the kidney . 
       Kidney shows the highest expression of HNF4A next to the liver (Sladek et al., 
1990). HNF4A is expressed exclusively in the proximal tubules (Jian et al., 2003). 
During embryonic development, the earliest proximal tubules arise during embryonic day 
14(e14) ( Stuart et al., 2000). HFN4A is present in this earliest stage of proximal tubule 
development. This shows that HNF4A serves an important function in the case of 
proximal tubules. In the adult, HNF4A expression is widespread in all proximal tubules 
(Jian et al., 2003). Proximal tubules are known to express GLUT2 (SLC2A2) which is 
required for glucose reabsorption. GLUT2 is a known target of HNF4A (Thomas et al., 
2004). Hence HNF4A could possibly be regulating GLUT2 in the proximal tubule. 
Furthermore it has been shown that in renal cell carcinoma HNF4A is downregulated (Sel 
et al., 1996). Expression of HNF4A in Human embryonic kidney 293(HEK293) cells was 
shown to reduce the cell proliferation rate (Lucas  et al., 2005).   
           Role of HNF4A in the kidney is relatively unknown. So far kidney specific 
knockout of HNF4A has not been carried out. In our study we attempted to investigate 
the relatively unknown function of HNF4A in the kidney. 
 
 




HNF4A is involved in the development of several metabolic diseases. The most well 
studied link to disease is maturity onset diabetes of the young (MODY). MODY is 
characterized by autosomal dominant form of inheritance and early onset, usually before 
25 years of age (Fajans et al., 1989). Rare mutations of HNF4A are known to cause 
MODY in some patient populations (Fajans et al., 1989). The major characteristic of 
MODY is that the pancreatic beta cells are unable to increase insulin production in 
response to hyperglycemia (Fajans et al., 1989).  Sequence polymorphisms in HNF4A 
have also been found to be linked to increased susceptibility to type 2 diabetes in some 
populations (Wanic et al., 2006). 
      The connection to diabetes has been confirmed in transgenic mouse models. Mice 
have been engineered to have beta cell specific knockout of HNF4A (Miura et al., 2006). 
These mice were seen to have normal pancreatic cell architecture. However they were 
seen to have impaired insulin secretion in response to hyperglycemia, similar to the 
MODY phenotype (Miura et al., 2006). The mechanism behind how HNF4A regulates 
insulin expression has been studied in vitro.  Bartoov et al (2002) has shown that HNF4A 
binds to the insulin promoter directly and drives expression. 
    Apart from diabetes, HNF4A has been shown to be involved in carcinogenesis (). 
HNF4A is known to be down regulated in renal cell carcinoma (Belén  et al., 2005). 
Lucas et al (2005) showed a tumor suppressor activity of HNF4A in kidney cells. 
Conditional overexpression of HNF4A in HEK293 cells was shown to reduce their 
proliferative capacity. Also by microarray technology they found the genes regulated by 
HNF4A. They found out that quite a number of the target genes identified are deregulated 
in renal cell carcinoma .  
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1.7  Acyl Coenzyme A dehydrogenase very long chain (ACADVL)  
 
Acyl Coenzyme A very long chain (ACADVL) is localized in the mitochondria. 
ACADVL is involved in the fatty acid oxidation pathway (Izai et al., 2005). ACADVL is 
unique among the Acyl Coenzyme A dehydronases in its specificity for very long chain 
fatty acids . Since ACADVL is the only enzyme active towards the very long chain fatty 
acids, there can be important consequences if ACADVL is disrupted. ACADVL has been 
linked to some cases of cardiomyopathy and other metabolic disorders. Mathur et al 
(1999) has identified ACADVL mutations in a group of children with cardiomyopathy, 
hypoglycemia, hepatic dysfunction, skeletal myopathy and sudden death in infancy. 
Animal models of ACADVL have further strengthened its role in the diseases mentioned. 
For example Cox et al (2001) created ACADVL knockout mice. It was found that the 
ACADVL deficient hearts presented with microvesicular lipid accumulation, 
mitochondrial proliferation and facilitated the development of ventricular trachycardia. 
The symptoms seen in the mice are similar to the human patients observed, thus showing 
that ACADVL is the causative factor for the human diseases mentioned. 
      Fatty acid oxidation is an important metabolic reaction in the kidney tissue. In some 
kidney diseases it is known to be deregulated. For example fatty acid levels have been 
found to increase in ischemic renal tissue, resulting in toxicity (Yamamoto et al., 2007) .  
Hence we wanted to investigate ACADVL in relation to the kidney diseases. Also we 
were interested in ACADVL because it was seen to be upregulated in Human embryonic 
kidney 293(HEK293) cells conditionally overexpressing HNF4A by microarray and 
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quantitative PCR (Lucas et al., 2005). Hence we wanted to test whether ACADVL is a 
direct target gene of HNF4A in the kidney.  Fatty acid oxidation is known to be affected 
in diabetes (Taylor et al., 1988). We wanted to test whether ACADVL expression is 
changed in diabetic nephropathy and the mechanism through which it occurs. We 




1.8    Objectives  
 
 
The objective of this study is to provide a deeper insight into the role of HNF4A and its 
potential target ACADVL in the normal and diseased kidney. We proceeded with this 
general objective using the following methodology. 
 
1 Analyzing the expression of HNF4A in a range of kidney diseases (diabetic     
nephropathy, acute rejection, IgA nephropathy, minimal change disease, acute tubular  
 injury, interstitial fibrosis and tubular atrophy, ischaemic/hypertensive nephropathy. 
2 Analyze the expression of potential HNF4A target gene Acyl Coenzyme 
dehydrogenase very long chain (ACADVL) in the disease cases. 
3 Prove that ACADVL is a target gene of HNF4A by identifying a response element for  
HNF4A in ACADVL. We used luciferase reporter assay to show that HNF4A activates 
ACADVL expression. PCR mutagenesis was used to mutate the putative HNF4A 
response element in the ACADVL sequence. 
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4 We wanted to investigate the effect of hyperglycemia on HNF4A promoter and 
ACADVL promoter.  This could provide us with the mechanism behind HNF4A and 
ACADVL up regulation during diabetes. 
5 Furthermore we wanted to knockout HNF4A in the kidney using Cre-lox technology. 











































2.1   Reagents 
 
All tissue culture media, reagents and solutions were obtained from Invitrogen Life 
Technologies, USA. All restriction enzymes were obtained from New England Biolabs, 
USA . K9218  antibody (cat no : ab54698) against HNF4A was obtained from Abcam, 
UK. Anti-ACADVL antibody (cat no : ab54698) . 
 
2.2 Cell Lines 
Human embryonic kidney 293 (HEK293) cell line was used in this study. HEK293 is a 
transformed human embryonic kidney cell line. HEK293 cells were cultured in 
Dulbecco’s modified Eagle’s medium(DMEM)  supplemented with 10% fetal bovine 
serum. Cells were maintained in 37 
0
C , 5% CO2  and 95% relative humidity. 
 
2.3 Vectors 
PGL3 luciferase reporter basic vector ( PGL3-Basic) was obtained  from Promega, USA 
and maintained according to instructions. pCI-neo mammalian expression vector was also 










2.4   Plasmids 
 
2.4.1 Expression plasmids 
PMT7-rHNF4.wt plasmid expressing full length HNF4ALPHA1 was a kind gift from 
Professor Frances Sladek (University of California , Irvine ). pCI-neo HNF4 ALPHA1   
expressing  full length rat HNF4ALPHA1 was  constructed by  subcloning  from PMT7-
rHNF4 to the vector pCI-neo at Xho1 and  Not1 restriction sites . 
2.4.2 Reporter plasmids 
Genomic DNA was extracted from HEK293 cells using Qiagen (USA) DNA extraction 
kit according to instructions. ACADVL -100/+1000 promoter was constructed by PCR 
amplifying from HEK293 genomic DNA using the primers (forward=5’-
gtagatctctccaggattggattgagc-3,reverse=5’gaaaagcttcgtccctcttgt cacacaca- 3’)  and cloned 
into linearised PG3-basic reporter vector and Hindiii and Bglii restriction enzyme sites . 
     ACADVL -195/+383 bp reporter construct was constructed by amplifying from 
HEK293 genomic DNA using the primers (forward=5’ GTGTAGATCTTAAG CA 
GCGGAACGCAG-3’, reverse=5’-GAAAAGCTTTTCCCCTAGTTTCGCCCTA- 3’. 
PCR product ws cloned into linearised PG3-basic reporter vector and Hindiii and Bglii 







2.5     Immunohistochemistry 
2.5.1 Patient biopsies 
Approval was obtained from National University of Singapore institutional review board 
prior to the study. We strictly followed the ethical guidelines advised by National 
University of Singapore. Biopsies from the renal cortex was obtained from 39 patients 
after obtaining informed consent.  Six cases with acute rejection, 5 cases with IgA 
nephropathy, 4 cases with diabetic nephropathy, 8 cases with acute tubular injury, 5 cases 
with institial fibrosis and tubular atrophy, 4 cases with minimal change disease, 2 cases 
with acute instertitial necrosis and 1 case with ischemic/hypertensive necrosis were used 
for the study. Healthy margin of the resected kidney from a renal cell carcinoma case was 
used as a control. Four control cases were used for the study. One biopsy was obtained 
for each case. 
2.5.2  Mouse model 
KK.Cg-Ay/J  type 2 diabetic mice were used for the study. C57bl6  wild type  mice were 
used as a control.  Two type 2 diabetic mice and two control mice were sacrificed at age 
of 4 months. All the mice used were male. After sacrificing the kidneys were fixed in 
10% buffered formalin and embedded in paraffin.  
 
2.5.3   Fixation and sectioning 
Kidneys were fixed in 10% buffered formalin overnight, dehydrated in ethanol. Then the 
kidneys were cleared in histoclear and embedded in paraffin. Subsequently the kidneys 
were sectioned at 4μm thickness using a microtome and captured on polysine slides 
(Fisher Scientific, USA) 
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2.5.4  Diaminobenzidine staining using ABC method . 
Section was permeabilized with 0.2% trixon-x for 10 minutes . It was blocked with 10% 
goat serum for 1 hour and avidin/biotin blocking was carried out using the avidin/biotin 
blocking kit from vector biolabs (USA) . Section was incubated with primary antibody 
overnight at 4 
0
c( mouse monoclonal k9218 ( ABCAM, UK , cat no : ab41898 ) to detect 
HNF4ALPHA and mouse monoclonal anti-ACADVL ( ABCAM , UK , cat no:ab54698 ) 
to detect ACADVL both at a concentration of 0.01 μg/ml ) . Section was washed with 
TBS and incubated with biotinylated anti mouse IgG (vector biolabs , USA ) at a dilution 
of (10μl / 2.5 ml diluent ). Section was washed again and incubated with vector ABC 
reagent for 1 hour. Section was washed with TBS 3 times and developed with 
diaminobenzidine substrate (vector biolabs , USA ) for 3 minutes. Subsequently the 
section was counterstained with Harris Hematoxylin (Sigma,USA) Then it was 
dehydrated , cleared and mounted in depex (vector biolabs , USA ). 
 
 2.5.5   Immunofluorescence using tyramide amplification and ABC method 
Section was permeabilized with 0.2% trixon-x for 10 minutes. It was blocked with 10% 
goat serum for 1 hour and avidin/biotin blocking was carried out using the avidin/biotin 
blocking kit from vector biolabs( USA ) . Section was incubated with primary antibody 
overnight at 4 
0
c (mouse monoclonal k9218 against hnf4alpha (ABCAM UK) at 10μg/ml, 
rabbit-anti-glut2( Millipore, USA ) at 1:200 dilution). Section was washed with TBS and 
incubated with biotinylated anti mouse IgG ( vector biolabs , USA ) at a dilution of (10 μl 
/ 2.5 ml diluent ) and goat-anti rabbit  fluorescein at 1:200 dilution and incubated for 3 
hours. Section was washed again and incubated with vector ABC reagent for 1 hour .  
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Section was washed 2 times with TBS and was incubated with Alexa-fluoro-tyramide at 
1:100 dilution. Section was washed with TBS, 3 times stained with Hoechst(Invitrogen) 
and mounted in fluoromount(Roche). Sections were stored in the dark at 4
0
C until image 
capturing using Confocal microscope  
 
2.6  Dual luciferase reporter assay 
HEK293 cells were plated at 500,000 cells per well of six well plate 1 day before 
transfection. Reporter plasmids and expression plasmids were transefected using 
Fugene(Roche , USA ) at a fugene to DNA ratio of 3:1 (v:v). Two days after transfection 
dual luciferase assay was carried out using the promega dual luciferase assay kit. Cells 
were washed with 1×PBS .  Cells were lysed with 60 μl per well of passive lysis 
buffer(provided in the kit). Lysate was cleared at 13000 rpm for 10 minutes. 20 μl of 
lysates was aliquoted into luminometer tubes.  LARII was prepared by suspending the 
provided luciferase assay substrate in 10ml of luciferase assay buffer II. Stop and Glo 
buffer was prepared by diluting Stop and Glo subtrate 50 times in Stop and Glo buffer . 
100 μl of luciferase assay reagent II (LARII) was added and firefly luciferase activity 
recorded. Subsequently 100 μl of Stop and Glo buffer was added and Renilla luciferase 
activity recorded. The ratio Firefly luciferase /Renilla luciferase was used for analysis 







2.7  Creation of HEK293 cells stably expressing HNF4ALPHA 
HEK293 cells were subcultured in 10cm plates at 60% confluency 1 day before 
transfection.  Transfected with HNF4ALPHA-pCI neo using Fugene (Roche , USA ) and 
control pCIneo vector at 1:3 DNA to fugene ratio. 48 hours after transfection cells were 
subcultured at 50% confluency . Subsequently the cells were put under G418 (Sigma , 
USA ) at a concentration of  0.2 μg/ml . Selective media was replaced every 2 days .  
10 Days after selection G418 resistant clones were observed.   At this stage the cells were 
partially trypsinised using 1/10 working concentration of trypsin.  After the clones 
detached they were picked and transferred to separate wells of a 96 well plate.  Cells 
were kept under G418 selection. After adequate growth, clones were transferred to 6 well 
plates . Subsequently each clone was checked for HNF4ALPHA expression by western 
blotting and frozen stocks were made of the positive clones until further use. 
 
2.8   Cell proliferation assay using CellTiter 96 cell proliferation assay 
 
HEK293 cells were plated in 96 well plates at 10,000 cells per well. Control wells were 
also included with medium alone . MTS solution equilibrated to room temperature . 20 μl 
of MTS solution to each well containing 100μl of medium.  Plates were incubated at 37 
0
c for 3 hours in a humidified, 5% CO2 atmosphere. Absorbance at 490nm was measured 
using an ELISA plate reader. The absorbance was normalized to absorbance in control 
wells containing medium only.  Cell survival was calculated as a percentage of 


















We decided to investigate the expression of hepatocyte nuclear factor 4 alpha(HNF4A) in 
a range of kidney diseases.  The tissue specimens are from patients admitted to National 
University Hospital (NUH). As a control we used nephrectomy samples(healthy kidney 
tissue taken from the margin of a renal carcinoma). We analyzed kidney tissue from 
diabetic nephropathy cases, acute rejection, IgA nephropathy, minimal change disease, 
acute tubular injury, interstitial fibrosis and tubular atrophy.  
            Before analyzing the disease cases we wanted to ensure that the immunostaining 
procedure only detects HNF4A in its correct localization . We first used 
immunofluorescence to show that the antibody used in this study (k9218) can detect 
HNF4A expressed at its correct localization. For this purpose we used Lotus Tetralobus 
lectin(LTL) which is a specific marker of proximal tubules.  
              As shown in fig 1 strong nuclear staining is observed for HNF4A in the human 
kidney. Colocalization of HNF4A and LTL shows that HNF4A is expressed in the 







      
                                                                 
Nephrectomy control stained with                      Nephrectomy control without primary  
anti hnf4alpha                                                      antibody- which serves as a negative                                     
                                                                             control  
 
Fig 1 : Fluorescence staining of HNF4A with Alexa fluo tyramide(red) and Lotus 
tetraglobus lectin(LTL) with fluorescein(green) in human nephrectomy control. DNA has 
been stained with Hoechst. Images were captured with a 1 Olympus FV300 at 60 × 




After having established the specificity of the antibody we stained the disease cases in 
batches. For each batch a control nephrectomy sample was included .   To our surprise we 
found that HNF4A is upregulated in the disease cases compared to the control .  Fig 2 
shows a representative image showing the extent of upregulation in diabetic nephropathy.  
To verify the finding the stained specimens were scored by a renal pathologist under 














3.1.1 HNF4A is upregulated in diabetic nephropathy 
Diabetic nephropathy is a chronic kidney disease . It is due to long standing diabetic 
mellitus . All diabetic nephropathy cases we analysed are of type 2 diabetes . We stained 
four cases of diabetic nephropathy with control sample. Only four cases were available 
due to scarcity of specimens . 
          Fig 2 shows representative images of stained sections. Visually inspecting , its 
clear that diabetic nephropathy has stronger staining compared to the control. This was 
confirmed by independent scoring by a trained renal pathologist under single blind 
conditions .  
         Fig 3 shows the scoring data for the diabetic nephropathy cases together with the 
control nephrectomy.  Percentage of stained nuclei out of the total proximal tubular 
nuclei is plotted for diabetic nephropathy cases and control nephrectomy.  Diabetic 
nephropathy has higher levels of strongly stained nuclei 27% compared to 1% in the 
control sample. Moderately stained nuclei are 34% out of total compared  to 24% in the 
control . Whereas there is 37% weakly stained nuclei in the diabetic cases compared to a 
much higher 70% in the control.   
      Overall diabetic nephropathy cases have more strongly stained nuclei compared to the 
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Figure 2 : Diaminobenzidine staining of HNF4A in diabetic nephropathy cases together 
with the control nephrectomy . All sections have been counterstained with hematoxyllin. 














     
Fig 3 :  Scoring data for diabetic nephropathy cases together with the control 
nephrectomy .  Stained sections were scored by a trained renal pathologist . Each section 
was scored separately. Number of nuclei which were strongly stained, moderately 
stained , weakly stained and those with no staining were counted in a randomly selected 
field of 100 proximal tubule cells . Figure represents the average scoring data for the four 




















3.1.2 HNF4A is upregulated in Acute renal rejection cases 
 
Acute renal rejection usually occurs one week after transplantation. The threat from acute 
rejection is highest in the first three months after transplantation. However it can also 
progress months to years after transplantation.  We stained six cases of acute renal 
rejection together with the control.  All cases were obtained from patients admitted to 
“National University hospital, Singapore”.  Fig 4 shows the representative images of 
acute rejection cases and the control . The patient cases have darker staining compared to 
the control. This was confirmed by independent scoring by a trained renal pathologist 
under single blind conditions.  
            Fig 5 shows the scoring data for acute rejection cases .  Average of the six cases 
are plotted together with the scoring for control nephrectomy cases . 25 %  of nuclei were 
scored as strongly stained compared to  3% in the control nephrectomy case . 34%  of 
nuclei were moderately stained for the patient cases compared to 23 % in the control. 
Control shows mostly weak staining at 69 % compared to 37% in the acute rejection 
cases. Roughly similar percentage show no staining in the acute rejection cases at 4% and 
the control at 5% . Overall it can be concluded that acute rejection cases show 
significantly darker staining compared to the control.  




                    
              Control nephrectomy              Acute rejection case 1  
                             
               Acute rejection case 2             Acute rejection case 3                                                                     
                              
                 Acute rejection case 4             Acute rejection case 5                                                                                                                 
                       
           Acute rejection case 6  
      Figure 4 : Diaminobenzidine staining of HNF4A in renal allograft rejection cases   
together   with the control nephrectomy sample. All sections have been counterstained with hematoxyllin. 




         
 
          Fig 5 : Scoring data for acute rejection . Staining results were scored by a renal   
          pathologist under single blind conditions.  Number of nuclei with strong, moderate,      
          weak and no staining were counted in a randomly selected field of 100 proximal  
           tubular cells.  Fig 5 represents the average of six cases analysed together with  





















3.1.3 HNF4A is upregulated in IgA nephropathy 
IgA nephropathy is primarily characterized by deposition of IgA antibody in the 
glomeruli . This results in the inflammation of the glomeruli. We stained four cases of 
IgA nephropathy together with the control. All specimens were obtained from patients 
admitted to “National University Hospital, Singapore”.  
       Fig 6 shows the representative images of stained patient sections together with the 
control. IgA nephropathy cases display darker staining compared to the control. This 
observation was validated by a trained renal pathologist by scoring the stained nuclei 
under single blind conditions. Figure 7 shows the scoring data for IgA nephropathy.  It 
represents the scoring data from four IgA nephropathy cases. 
         17% of nuclei in IgA cases show strong staining compared to 3% in the control . 
34% of the nuclei are moderately stained in the IgA nephropathy and 23% are moderately 
stained in the control.   In the control most nuclei are weakly stained ( 69% ) whereas in 
the IgA nephropathy cases only 37.6% are weakly stained. In the IgA cases 12% nuclei 
show no staining compared to 5% in the control case.  
          On average it can be concluded that IgA cases have stronger staining compared to 








                                           
                             Control nephrectomy                 IgA nephropathy case 1  
                                          
                             IgA nephropathy case 2            IgA nephropathy case 3                                        
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Figure 6 : Diaminobenzidine staining of HNF4A in IgA nephropathy cases and control 
nephrectomy case. All sections have been counterstained with hematoxyllin. Images have 



















 Figure 7 : Scoring data for IgA nephropathy. 
Staining results were scored by a renal pathologist under single blind conditions.  
Number of nuclei with strong, moderate,weak and no staining were counted in a 
randomly selected field of 100 proximal tubular cells.  Figure represents the average of 





















3.1.4   HNF4A is upregulated in “Minimal change” kidney disease 
 
 
“Minimal change” is a kidney disease that can lead to nephritic syndrome . The name 
minimal change is conferred to this disease because there is no structural change 
observed in the nephron.  Minimal change is the most common nephritic syndrome in 
children , it is also seen in adults .  
         We stained for HNF4A in four cases of minimal change disease together with one 
control .  Biopsies were obtained from patients admitted to “National University Hospital, 
Singapore” . Fig 8 shows representative images of staining from the four cases of 
minimal change and the control .  Darker staining can be observed in the patients 
compared to the control.  
        This is corroborated by independent scoring by a trained renal pathologist under 
















                 
Control Nephrectomy                     Minimal change case 1  
                      
 Minimal change case 2                   Minimal change case 3   
 
 
   Minimal change case 4   
 
 Fig 8: Diaminobenzidine staining of Minimal change cases and control nephrectomy 
All sections have been counterstained with hematoxyllin. Images have been captured 



















Fig 9 Scoring data for Minimal change kidney disease . 
Staining results were scored by a renal pathologist under single blind conditions.  
Number of nuclei with strong, moderate,weak and no staining were counted in a 
randomly selected field of 100 proximal  tubular cells.  Figure represents the average of 


















3.1.5  HNF4A is upregulated in acute tubular injury 
 
 
Acute tubular injury is a common and devastating condition in hospitalized patients. 
Diagnostic tests for acute tubular injury include serum creatinine and blood urea nitrogen. 
In acute tubular injury the kidney still retains its ability to do its major function, which is 
glomerular filtration .  
         We stained HNF4A in five cases of acute tubular injury together with the control.  
The specimens are from patients admitted to “National University Hospital, Singapore”.    
Fig 10 shows representative staining images from acute tubular injury cases together with 
the control section. It can be observed that there is darker staining in the acute tubular 
cases compared to the control.  
          This was confirmed by independent scoring by a trained renal pathologist .  
 Fig 11 shows the average of the four acute tubular cases expressed as a percentage 
together with the control. 23% of the nuclei in the acute tubular cases show strong 
staining compared to 0% in the control section. 39% of the nuclei in the patient cases 
show moderately dark staining compared  to 5 % in the control nephrectomy . Control 
section shows mostly weak staining at 80% of the total nuclei compared to 36% in the 
actute tubular injury . Less than 1% of the nuclei in the patient sections show no staining 
compared to 15% of the nuclei in the control. It can be concluded that there is darker 
HNF4A staining in the acute tubular injury cases compared to the control. Therefore 





              
             Control nephrectomy                       Acute tubular injury case 1   
                                        
            Acute tubular injury case 2             Acute tubular injury case 3    
               
            Acute tubular injury case 4              Acute tubular injury case 5    
 
 
   Fig 10 :   Diamino benzidine staining of acute tubular injury 
All sections have been counterstained with hematoxyllin. Images have been captured    



















Fig 11 : Scoring data for acute tubular injury cases 
 Staining results were scored by a renal pathologist under single blind conditions.  
Number of nuclei with strong, moderate,weak and no staining were counted in a 
randomly selected field of 100 proximal  tubular cells.  Figure represents the average of 













3.1.6  HNF4A is not significantly changed in Interstitial fibrosis and tubular  
          atrophy(IFTA) 
 
 
Interstitial fibrosis is considered to be present when the supporting connective tissue 
exceeds  5%  of the cortex. In tubular atrophy, there are tubules with thick redundant 
basement membranes or significant reduction in tubular diameter . We stained for 
HNF4A in four cases of IFTA together with the control. All samples are from patients 
admitted to “National University Hospital, Singapore” . Informed consent had been 
obtained before sample collection.  Fig 12 shows the diamino benzidine staining IFTA. 
There is no significant variation in staining intensity between the IFTA cases and control 
nephrectomy 
              This was confirmed by independent scoring by a trained renal pathologist . 
Fig 13 shows the average of the four IFTA cases expressed as a percentage together with 
the control nephrectomy. No significant difference can be seen in the IFTA cases and 
control.  
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Fig : 12 Diamino benzidine staining of Interstitial fibrosis and tubular atrophy(IFTA) 
All sections have been counterstained with hematoxyllin. Images have been captured    



















Fig :13  Scoring data for interstitial fibrosis and tubular atrophy (IFTA) 
Staining results were scored by a renal pathologist under single blind conditions.  
Number of nuclei with strong, moderate,weak and no staining were counted in a 
randomly selected field of 100 proximal  tubular cells.  Figure represents the average of 















3.2   Increased Acadvl( Acyl Coenzyme A very long chain) levels in type 2  
 
        diabetic mouse model 
 
 
After showing that HNF4A is upregulated in a range of the kidney diseases, we wanted to 
focus our attention on diabetic nephropathy. We were interested in investigating which 
target genes of HNF4A might be upregulated in diabetic conditions .  Acyl Coenzyme A 
very long chain(ACADVL) is suspected to be a target of HNF4A. ACADVL has been 
shown to be upregulated in HEK293 cells overexpressing HNF4A(Lucas et al., 2005). 
Furthermore ACADVL is involved in fatty acid oxidation pathway which is known to be 
affected in diabetes(Taylor et al., 1988) . Hence ACADVL was an attractive target to 
investigate. 
 
3.2.1 ACADVL staining  is increased in type 2 diabetic mouse model 
We hypothesized ACADVL is upregulated in type 2 diabetic mice model. We carried out 
immunostaining to test this hypothesis. There was significant increase of ACADVL in 
diabetic kidney compared to the control mice which has light or absent staining(Fig 14) 
















    
First type 2 diabetic mouse  kidney cortex        First control c57bl6  kidney cortex 
                                                                                                                            
    
Second type 2 diabetic mouse kidney             Second control c57bl6  kidney cortex 
cortex 
                                                                                                                      
             
                        
 Figure 14:  Diaminobenzidine staining of acadvl in type 2 diabetic mice model and 
control mice .  Two  KK.Cg-Ay/J type 2 diabetic mice and 2 wildtype c57bl6 mice were 
sacrificed and kidneys were fixed . Subsequently the sections were stained for ACADVL . 






3.2.2   ACADVL staining is increased in proximal tubules . 
Since HNF4A is exclusively expressed in the proximal tubules .  We wanted to see 
whether the increased ACADVL staining is mainly in the proximal tubules. For this we 
used a Lotus Tetralobus Lectin(LTL) which is a specific marker of proximal tubules.  We 
used LTL tagged with fluorescein and secondary antibody tagged with texas red to 
colocalize ACADVL and LTL. LTL stains the apical membrane of proximal tubules. 
ACADVL staining is seen to increase in some of the LTL positive tubules as shown in fig 
15 .  Staining is mainly basolateral in nature as shown by the arrow. This is expected 
since ACADVL is localized in the mitochondria which are known to beconcentrated near 
basolateral membrane in proximal tubules . No primary control shows no red color 
staining for ACADVL, showing that the observed staining is specific and not due to 
background. 
 
3.2.3  ACADVL staining is increased in human diabetic nephropathy cases 
 
Having shown that ACADVL is upregulated in diabetic mouse model, we wanted to stain 
the human diabetic nephropathy cases. As shown in fig 16. Two out of four human 
diabetic nephropathy cases show increased ACADVL staining. We have previously 
shown the HNF4A is upregulated in these patients. Hence its likely that increase in 
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Type 2 diabetic mouse 2 kidney cortex      Type 2 diabetic mouse 2 kidney cortex                                                                               
 ACADVL(red)    LTL(green)                     no primary antibody control 
 
                                    
 
Fig 15:  ACADVL is expressed in LTL positive proximal tubule cells        
 
Sections from Type 2 diabetic mouse 2 kidney cortex were subjected to 
immunofluorescence staining with anti-acadvl antibody and lotus tetralobus lectin 
( LTL)-fluorescein(green) . ACADVL(red) was detected with texas-red conjugated to 
secondary.  Arrow in panel A indicates the basolateral localization of ACADVL. DNA 
has been stained with Hoechst. Images were captured with a 1 Olympus FV300 at 60 × 





















     
                Control nephrectomy                Diabetic nephropathy case 1  
 
       
         Diabetic nephropathy case 2         Diabetic nephropathy case 3   
 
 
    Diabetic nephropathy case 4    
 
 Fig 16: Diamino benzidine staining for ACADVL in human diabetic nephropathy 
 Four cases of diabetic nephropathy were stained for ACADVL. Two out of four cases 
demonstrated upregulation as indicated by the arrows in the figure. All sections have 
been counterstained with hematoxyllin. Images have been captured with Olympus CKK 










3.3  Novel HNF4A response element is identified in Acyl Coenzyme Dehydrogenase 
Very Long Chain(ACADVL) sequence 
 
 
After showing that both HNF4A and ACADVL are upregulated in diabetic conditions. 
We wanted to test whether ACADVL is a direct target of HNF4A. This would show us 
whether ACADVL is upregulated in diabetes due to increased levels of HNF4A. 
As stated earlier it has been shown that ACADVL is upregulated in the kidney cell line 
HEK293 overexpressing  HNF4A(Lucas et al., 2005). However to show that ACADVL 
is a direct target, response elements to HNF4A must be identified the ACADVL sequence.  
               Visually inspecting the ACADVL 5’ untranslated sequence, we identified a 
putative HNF4A binding site AGGTCCCAAGGCA  950 bp upstream of the start ATG . 
We cloned -1000 to +100 bp with respect to start ATG of ACADVL from HEK293 
genomic DNA into the pgl3 reporter vector . We tested the above construct in HEK293 
for transactivation by HNF4A using dual luciferase assay. We used the artificial promoter 
construct Pzlhiv with four HNF4A binding sites as a positive control for HNF4A 
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3.3.1   Putative HNF4A site at -950bp is non active 
Fig 17 shows the relative activation with Pzlhiv construct alone given an arbitrary value 
of 10.  There is no activation with   HNF4A for -1000/+100bp promoter construct , 
showing that the identified site is non active .  
 -                               
                       
                       
Pzlhiv                                 +                    +                   -                     - 
-1000/+100bp construct     -                     -                   +                     + 
HNF4A-pcineo                   -                     +                   -                     +      
 
 
Fig 17 : Dual luciferase reporter assay for -1000 bp /+100bp promoter construct. Dual 
luciferase was carried out using Promega dual luciferase kit. Experiment was carried out 
in triplicate wells . Pzlhiv reporter without HNF4A was give an arbitrary value of 100. 
The other values were normalized to this. Each value has been normalized to renilla 






3.3.2  Two potential HNF4A response elements distal to start ATG in ACADVL 
On further analysis of the ACADVL genomic sequence we identified two putative 
HNF4A binding sites in the coding sequence.  One at +332 bp with respect to start ATG 
and the other at +370 bp . On subjecting the sequence to TFSearch algorhythm the +370 
bp site came as a highly likely site.  The +332 bp site is ( AGGGGAAAGGGCA) and the 
+370 bp site is (AGGGGAAAGGTCA ) .  The two sites differ only by one nucleotide at 
the 11
th
 position.   
        To test whether any of the site are actively regulated by HNF4A we cloned -195 bp 
to +385bp of ACADVL genomic sequence in to pgl3 reporter. This construct should 
contain the minimal promoter as reported in Zhang et al (2003). When we tested this 
construct for HNF4A transactivation. There was ~ 4 fold activation in the presence of 
HNF4A . In this case also we used the artificial pzlhiv construct with four HNF4A 
binding sites as a positive control.  Fig 18 shows the relative activation with PZLhiv 
construct alone given an arbitrary value of 100 .  Pzlhiv construct is activated ~8 fold by 



















3.3.3      -195bp/+383bp reporter with two putative HNF4A responsive elements 
               is activated by HNF4A 
 
 
                                    1
st
 site  for  HNF4A                    2
nd
 site for HNF4A 
 




                   
 
Pzlhiv                               +                      +                        -                       - 
-195,+383bp construct      -                      -                         +                     + 
Hnf4alpha-pcineo             -                      +                         -                     +      
 
 
Fig 18: Dual luciferase reporter assay for -195 bp , +383 bp promoter construct 
Dual luciferase was carried out using Promega dual luciferase kit. Experiment was 
carried out in triplicate wells . Pzlhiv reporter without HNF4A was give an arbitrary 
value of 100. The other values were normalized to this. Each value has been normalized 







             
 
3.3.4   HNF4A response element at  +370bp in ACADVL sequence is active 
 
         To identify which of the putative sites is active towards HNF4A, we created a 
deletion mutant lacking the +370bp response element but still having the +332bp 
response element is intact .  Our finding was that there is no activation in the presence of 
HNF4A for this reporter construct(Fig 19).  
 
 
        
       
          
Pzlhiv                              +                        +                        -                        - 
-195,+377bp construct    -                         -                        +                        + 
 Hnf4alpha-pcineo           -                        +                        -                        +     
 
Fig 19 : Dual luciferase reporter assay for -195 bp-+377 bp deletion construct 
Dual luciferase was carried out using Promega dual luciferase kit. Experiment was 
carried out in triplicate wells . Pzlhiv reporter without HNF4A was give an arbitrary 
value of 100. The other values were normalized to this. Each value has been normalized 







      Hence +370 bp site which was identified by TFsearch is the active HNF4A response 











































3.4     GLUT2 and HNF4A are colocalized in the proximal tubule 
 
Glut 2 ( Glucose transporter 2 ) is an established target of HNF4A in the liver .  
For HNF4A to regulated GLUT2, they should be expressed in the same cell. Its not 
known whether GLUT2 and HNF4A colocalize in the kidney. We decided to investigate 
the localization of GLUT2 in relation to HNF4A .  Fig 20 Shows GLUT2 expression in 
green and HNF4A expression in red . GLUT2 is seen to be basolaterally expressed.  
 
                        
 
                                                                                
Fig 20: HNF4A and  GLUT2(SLC2A2) co-localisation. HNF4A and is stained with 
alexafluoro tyramide staining(red) and GLUT2 with fluorescein conjugated 
secondary(green).  They are seen to co-localize in S1 proximal tubules. Basolateral 









3.5   GLUT2 is mislocalized and upregulated in diabetic mice 
 
GLUT2 is a known target gene of HNF4A. We were interested in studying the expression 
of GLUT2 in diabetic condition. As shown in Fig 21, there is more intense staining of 
GLUT2 in the diabetic mice compared to the control.  In the control, Glut2 is mainly 
expressed in the basolateral membrane(shown by arrow in Fig 21 panel A). We used 
Lotus tetralobus lectin(LTL) as a marker of apical membrane. In the diabetic mice, 
GLUT2 is also expressed in the apical membrane, as shown by the arrow in Fig 21 panel 
B(colocalization with LTL(green). 
 
   
                                                                                                                  
Control C57bl6 kidney cortex                        KK.Cg-Ay/J type 2 diabetic mice  
                                                                                                kidney cortex 
                        Panel A                                                                 Panel B 
 
Figure 21:  GLUT2 upregulated and mislocalized in type 2 diabetic mice 
 
Kidney sections from  c57bl6 mice and KK.Cg-Ay/J type 2 diabetic mice were subjected 
to immunofluorescence staining using rabbit-antiglut2 and texas red conjugated 
secondary s . Lotus  tetralobus lectin (LTL)-fluorescein(green) was used to stain apical 







3.6    Increased Reactive Oxygen Species(ROS) stress in diabetes 
We wanted to investigate the mechanism of HNF4A upregulation in these disease 
conditions.  Increase in oxidative stress is a common factor in these conditions since there 
is often a inflammatory redox status present(Ha et al., 2001) .  Since previous studies 
have shown that increase in ROS stress can upregulate HNF4A (Quadri., 2006), we 
proceeded to investigate the ROS status in diabetic nephropathy .  We used nitrotyrosine 
staining as a biomarker of oxidative stress.  
3.6.1   Increased nitrotyrosine staining in diabetic mice 
First we stained for nitrotyrosine in the diabetic mice model. As shown in Fig 22 there is 
significantly increased staining in the diabetic mice compared to the control mice. Nitro 
tyrosine staining is mainly observed in the tubules both distal and proximal.. In contrast 
nitrotyrosine staining is light or absent in the glomeruli. 
3.6.2  Increased nitrotyrosine staining in human diabetic nephropathy cases 
We also stained the human diabetic nephropathy cases . Significantly increased 
nitrotyrosine staining was observed for the four diabetic nephropathy cases  compared to 
the control(Fig 23)Similar to the mice, staining was observed in both distal and proximal 














        
                                                                                                                            
                            Control c57bl6                                          Type 2 diabetic ob/ob 
 
Fig 22:    Increased nitrotyrosine staining in type 2 diabetic mice mice 
 
Increased nitrotyrosine staining in Type 2 diabetic mice compared to the control mice. 
Diabetic nephropathy cases were stained together with the control nephrectomy   rabbit 
anti nitrotyrosine was used in the above experiment. Nitrotyrosine is a marker of 
oxidative stress. Positive staining is indicated with arrows. Sections have been 
counterstained with hematoxyllin for contrast.Images have been captured with Olympus 


















                                             
                                 Control nephrectomy           Diabetic nephropathy case1 
                                                                                                                
                             Diabetic nephropathy case 2                Diabetic nephropathy case 3       
                                           
                Diabetic nephropathy case 4                                                        
              
Fig 23 : Increased nitrotyrosine staining in diabetic nephropathy cases . 
Diabetic nephropathy cases were stained together with the control nephrectomy . Rabbit 
anti-nitrotyrosine was used in the above experiment. Nitrotyrosine is a marker of 
oxidative stress. Positive staining is indicated with arrows. Images have been captured 
with Olympus CKK 41 microscope  at  40×magnification. Arrows indicate example of 
positive staining. 
 








3.7   Effect of increased glucose levels on HNF4A 
 
Since we have shown that HNF4A levels and one of its targets Acadvl are upregulated in 
diabetic conditions, we wanted to investigate the mechanism through which this 
phenomenon arises. Diabetes is characterized by constant hyperglycemia. We 
hypothesized that the hyperglycemia has an effect on HNF4A and its targets. First we 
tested HNF4A promoter in the presence of 5mM and 25mM d-glucose.  In all 
experiments total glucose was topped up to 25mM with L-glucose which is metabolically 
inactive. This to keep the osmolarity constant.   
 
3.7.1   Effect of high glucose on HNF4A promoter 
As shown in Fig 24 there is ~50 % in increase in reporter activity with 25 mM d-glucose 
compared to 5 mM d-glucose . Hence HNF4A promoter activity is increased in the 
presence of high glucose. Therefore more HNF4A would be expressed from the HNF4A 















      





















































              
Hnf4alpha promoter            +                  +                      
 
Fig 24: Dual luciferase reporter  for HNF4A promoter in pgl3 vector in high glucose 
Assay was carried out in the presence of 5 mM d-glucose and 25 mM d-glucose. 
Luciferase units is plotted which has been normalized to renilla luciferase . HEK293 cells 




3.7.2   Effect of high glucose on artifical HNF4A target promoter 
Next we tested the pzlhiv reporter construct with 4 artificial HNF4A binding sites.  With 
the reporter alone glucose concentration has no effect . However when HNF4A is 
expressed , reporter activity increases 55% when we increase d-glucose from 5 mM to 25 
mM(Fig 25) .  The implication of this result is that any gene with HNF4A response 









Effect of high glucose on hnf4a transactivation







































Pzlhiv reporter            +        +                    +        + 
  HNF4A-pcineo           -        -                     +        + 
 
  
Fig 25:  Dual luciferase reporter assay for Pzlhiv reporter with four artificial HNF4A 
binding sites. Assay was carried out in the absence and presence of HNF4A with 5mM 
and 25mM d-glucose.  In all cases total glucose was topped up to 25mM with L-glucose. 
HEK293 cells were used for this assay.  Relative luciferase units have been normalized to 
renilla luciferase .           
        
 
3.7.3   Effect of high glucose on ACADVL  promoter 
 We also tested the HNF4A responsive ACADVL reporter construct in the same manner.  
In this case the observation was similar . With the reporter alone, glucose concentration 
doesn’t effect the activity . However in the presence of HNF4A, reporter activity 
































































Acadvl promoter     +        +                                +        + 




Fig 26:Dual luciferase assay for HNF4A responsive ACADVL promoter in pgl3 reporter 
under high glucose . 
 Experiment was carried out in the absence and presence of HNF4A with 5 mM d-
glucose and 25 mM d-glucose . All luciferase units have been normalized to renilla 
luciferase . ACADVL reporter with no HNF4A under 5 mM d-glucose( column 1) has 























3.8    HNF4A  reduces cell survival under high glucose conditions 
 
Cell proliferation was analysed by MTS(3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assay. MTS in the presence 
of PMS(phenazine methosulfate) is reduced to a water soluble formazan product by 
metabolically active cells.  The absorbance of formazan at 490nm is directly proportional 
to the number of living cells in culture.   
        HEK293 cells stably expressing HNF4A and control cells stably integrated with 
vector were used for these experiments. Before each experiment it was checked whether 
there is sufficient expression of HNF4A. The cells were always kept under G418 
selection to make sure that the integrated construct is not lost.  
           We used d-glucose concentrations of 25 mM and 50 mM for the treatment. Total 
glucose was topped up to 50 mM with L-glucose. This ensures that the osmolarity is kept 
constant. For wild type HEK293 cells there is around 20% reduction in cell cell survival 
after 2 days of 50 mM glucose(Fig 28) .In the case of HEK293 overexpressing HNF4A, 
there is around 35% reduction in cell survival with 50mM glucose treatment(Fig 27). 
This implies that HNF4A overexpression increases high glucose induced cell death. 
There is around 15% increase in cell death due to HNF4A overexpression in the presence 



















Fig 27:MTS assay for HEK293 cells stably overexpressing HNF4A and control cells 
integrated with pci-neo vector. Cells were treated with 50 mM d-glucose and cultured for 
2 days. MTS assay was carried out at 0 hour , 24 hour and 48 hours . Each data point 






















3.9  Creation of proximal tubule specific HNF4A knockout mice 
 
 
We wanted to create a proximal tubule specific knockout of HNF4A. For this we used 
Cre–Lox  technology . The lox and Cre mice were obtained commercially. HNF4A lox 
line was obtained from Jackson labs(USA) and Sglt2-cre mice from EMMA(European 
Mouse Mutant archive, France). The HNF4A-lox mice have Loxp sites flanking exon 3 
and 5 of HNF4A. It had been used before to create liver specific knockout of HNF4A 
(Battle  et al., 2006).  
                   Sglt2-Cre expresses Cre recombinase under Sglt2 promoter which expresses 
Cre in S1 segment of the proximal tubule.  First we crossed the HNF4A-LOX and Cre 
mice to obtain the F1 generation . The F1 generation are of the genotype(HNF4A WT 
/HNF4A lox, Sglt2-Cre). For the knockout to work both alleles should be HNF4A-lox. 
Hence we crossed the F1 generation to HNF4A-LOX/HNF4A-LOX  to obtain (HNF4A-
lox / HNF4A-lox, Cre ) genotype.   
              Fig 29 Shows the representative genotyping result of a F2 litter.  Expected 
mendelian ratios were obtained for the progeny. Around 1/8 th of the litter were of the 
genotype( HNF4A-Lox/HNF4A-Lox, Sglt2-Cre) which is expected to have HNF4A 
knocked out in the proximal tubule(Fig 29, lane 1, 2 and 7). We immunostained  the 
kidney tissue from these mice for HNF4A. Proximal tubules are stained with LTL-
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fluorescein(Fig 30).  However, HNF4A expression was still present in all proximal 











Fig 29 : Representative genotyping results for the mice. Lanes1, 2 and 7 are theoretically 
expected to have proximal tubule specific knockout of HNF4A. 
 
 
         
                                                                                                         
 
               HNF4ALOX/HNF4ALOX                HNF4ALOX/HNF4ALOX 
    Wild type      Sglt2-Cre 
                                                                           (Expected to be proximal tubule specific   
                                                                             knockout of HNF4A) 
 
 Fig 30  Immunofluorescence staining for potential proximal tubule specific HNF4A knockout 
mice. Both wild type and expected knockout mice have strong HNF4A staining(red) in the 
nuclei as indicated by arrows. Hence knockout is unsuccessful.All Lotus tetralobus lectin(LTL) 
















 4           DISCUSSION 
 
 
This study is directed at generating deeper insight into the involvement of Hepatocyte 
Nuclear Factor 4 A(HNF4A) in the normal and diseased kidney. For this purpose we 
stained HNF4A in a range of kidney diseases. Then stained one of its known targets 
GLUT2 and suspected target ACADVL. Furthermore we carried out reporter asay of 
ACADVL promoter to investigate the transactivation capacity of HNF4A on ACADVL. 
Novel response element for HNF4A was identified in the ACADVL sequence by 
deleting the site and subsequent reporter assay. In addition reporter activity of HNF4A 
and ACADVL promoter was carried out under high glucose condition to study whether 
the upregulation in diabetic nephropathy is due to the hyperglycemia. We also attempted 
to knockout HNFA in the kidney using Cre-lox technology. 
 
4.1   Increased proximal tubular HNF4A expression in nephropathies 
      We  have shown by immunostaining that HNF4A is upregulated in a range of kidney 
diseases. This result was confirmed by a trained renal pathologist by scoring of stained 
nuclei.  Futhermore the result was confirmed by automated scoring of the staining. 
Previously researchers have used scoring of stained nuclei to analyze the staining. For 
example (Ong et al., 2010) used visual and automated scoring to identify biomarkers 




HNF4A is known to play important roles in a variety of cellular and physiological 







4.1.1  Implications of HNF4A upregulation in diabetic nephropathy 
As shown in Fig 2 and Fig 3, HNF4A is significantly upregulated in the diabetic 
nephropathy cases analyzed. We had access to only four cases. However HNF4A is 
upregulated in every case consistently compared to the control. 
       This HNF4A upregulation can have metabolic and cellular consequences.  It is 
known that HNF4A is involved in gluconeogenesis(Rhee et al., 2003). HNF4A regulates 
gluconeogenesis by regulating gluconeogenic enzymes such as Phosphoenol Pyruvate 
Carboxy Kinase(PEPCK)(Wang et al., 1999). Hence increase in HNF4A can lead to 
increased rate of gluconeogenesis in diabetic nephropathy. It has been shown that renal 
gluconeogenesis is enhanced in human diabetic patients(Meyer et al., 1998). Increased 
renal gluconeogenesis has been shown in animal model of diabetes as well(Eid et al., 
2006) . This effect can have important pathological effects for the diabetic patients, since 
the hyperglycemia would be elevated . 
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         Our finding, that HNF4A is upregulated offers a potential mechanism by which 
renal gluconeogenesis would be elevated in diabetes. Increased HNF4A would lead to an 
increase in the gluconeogenic enzyme PEPCK, thus leading to elevated gluconeogenesis. 





If we suppress the expression of HNF4A or inhibit its activity using a pharmacological 
inhibitor, we may be able to lower the gluconeogenesis rate in diabetes.  
 
4.1.2   Implications of HNF4A upregulation in Acute renal rejection, IgA 
nephropathy,  Minimal change disease and Acute tubular injury 
 
We have shown by immunostaining, that HNF4A is upregulated in acute renal rejection, 
IgA nephropathy, minimal change disease and acute tubular injury . This finding was 
confirmed by a renal pathologist by scoring the stained nuclei. We couldn’t analyze a 
large number of cases due to lack of specimens. We observed consistent upregulation in 
all cases studied.  
         This upregulation can have important complications for these disease conditions.  
As in the diabetic nephropathy, HNF4A upregulation may lead to metabolic effects.  
Another possibility is that increased HNF4A will contribute to increased inflammatory 
reaction. A common condition in these disease conditions is hyper activation of the 
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immune system. For example in acute renal rejection, immune system would attack the 
transplanted kidney(Heering et al., 1996). In IgA nephropathy there is inflammation of 






              HNF4A takes part in the inflammatory reaction by regulating inducible Nitrogen 
Oxide Synthease( iNOS) (Guo et al., 2006). In fact iNOS is known to be upregulated in 
some of these diasease conditions.  It is  known that iNOS is elevated in acute renal 
rejection.  In IgA nephropathy also iNOS was seen to be elevated and was found to 
contribute to inflammation and apoptosis(Qui et al., 2004).  The mechanism of iNOS 
upregulation in these disease conditions was not known. Our finding offers a potential 
mechanism, where elevated HNF4A would lead to increased iNOS expression. 
 
       
     
           
         If we are able to lower the expression of HNF4A or inhibit it’s activity by using a 
pharmacological inhibitor, we can bring down iNOS expression in these kidney diseases, 
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hence lowering inflammation. It would be possible to reduce the inflammatory reaction 







4.2     Acyl Coenzyme A dehydrogenase very long chain (ACADVL) upregulation    
          in diabetic kidney 
 
4.2.1   ACADVL upregulation in type 2 diabetic mice 
ACADVL is involved in the fatty acid oxidation pathway . It shows activity towards very 
long chain fatty acids (Izai et al., 2005). Previous work by Tilton et al(2007) has shown 
that ACADVL is upregulated in Leprdb (db/db) type 2 diabetic mice by two dimensional 
electrophoresis. Two dimensional electrophoresis is a high throughput method which is 
useful as an initial screen. However it is known to produce false positives due to the 
nature of the assay. 
          As shown in Fig 13 ACADVL is upregulated in type 2 diabetic mice compared to 
the control . In our approach we used an antibody which is known to be specific to 
ACADVL . Hence our finding corroborates the previous finding.  Furthermore we have 
extended the finding to a different mice model of type 2 diabetes(KK.Cg-Ay/ strain). 
This further strengthens the hypothesis that upregulation of ACADVL is a common 
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finding in type 2 diabetes and not specific to Leprdb (db/db) diabetic mice model used by 
Tilton et al (2007) .  
 
 
4.2.2   ACADVL is upregulated in proximal tubules in diabetes 
       We hypothesized that ACADVL is upregulated by the action of HNF4A.  For this 
hypothesis to be true,  ACADVL and HNF4A need to be expressed in the same cell.We 
showed by colocalization with Lotus Tetralobus Lectin(LTL), that ACADVL is 
expressed in the proximal tubule cells Fig 14 . LTL is a specific marker of proximal 
tubules(Cheng et al., 2006). Its already known that HNF4A is expressed in the proximal 
tubules. Hence ACADVL and HNF4A are both expressed in the proximal tubules. 
Therefore HNF4A can be regulating ACADVL in proximal tubular cells.  
 
4.2.3   ACADVL is upregulated in human diabetic nephropathy 
As shown in Fig 15 ACADVL is also upregulated in 2 out of 4 diabetic nephropathy 
cases. We have already shown that HNF4A is upregulated in these diabetic nephropathy 
cases. Hence its highly likely that ACADVL is upregulated in response to higher levels 
of HNF4A in human diabetic nephropathy. Only two out of four cases show 
upregulation . This may be because there may be other complicating factors preventing 
ACADVL levels to increase in the other patients. Previously it has been shown that  
there is derangement of lipid metabolism in diabetes(Raz et al., 2005) . Our finding that 
fatty acid oxidation gene ACADVL is upregulated in diabetes gives another route by 




4.2.4    Implications of ACADVL upregulation for diabetes 
ACADVL  is involved in the beta oxidation of very long fatty acids (Izai et al., 2005) .   
In the diabetic state there are higher levels of free fatty acids in the blood (Jellinger et al., 
2007). Increased ACADVL may lead to faster oxidation of these fatty acids resulting in 
the accumulation of Acetyl-CoA .  
                            
                            
        Accumulation of Acetyl-CoA is known to result in ketogenesis, where ketone 
bodies are formed and released to the systemic circulation.  Accumulation of ketone 
bodies can lead to ketoacidosis where the blood turns acidic leading to serious 
complications(Felig et al., 1974). Hence ACADVL upregulation in diabetes can 





         Our findings may offer us a solution to the ketoacidosis in diabetes. Since we found 
that ACADVL levels are increased in diabetic conditions, if we can lower ACADVL 
expression we might be able to prevent ketoacidosis in diabetes.  
 
4.3    Novel HNF4A response element in ACADVL  promoter 
Since HNF4A upregulates ACADVL in HEK293 cells(Lucas et al., 2005), we wanted to 
investigate whether HNF4A directly regulates the ACADVL transcription.  Zhang et 
al(2003) has cloned the minimal promoter of HNF4A. Zhang et al(2003) has shown that 
AP2 can drive the ACADVL minimal promoter. Apart from this work not much work 
has been done on ACADVL promoter. As of yet we do not know which transcription 
factors are driving the expression of ACADVL. HNF4A is known to regulate a range of 
genes involved in lipid  metabolism. For example it regulates HMG-CoA , apoliprotein 
(Rhee et al., 2006) , Hence HNF4A was a good candidate to be tested for regulating 
ACADVL .  
        Three possible HNF4A binding sites were identified in the ACADVL sequence. 
One at -950bp with respect to the start ATG, another at +332 and the last one at +370 bp. 
Fig 16 shows that the site -950 bp has no activation by HNF4A .  However the second 
reporter construct  containing +332 site and +370 site shows ~6 fold activation with 
HNF4A(Fig 17). Deleting the +370 site abrogates the HNF4A transactivation proving 





              Acadvl sequence with the response elements. +370 site is functional 
 
       Most transcription factors bind to -1000 bp to +100 bp with respect to the 
transcription start site (Odom et al., 2004).  However some transcription factors are 
known to bind to response elements distal to the start ATG. For example Hao et al(2003) 
has identified a glucocorticoid response element  at +434 with respect to the transcription 
start site in exon IV of K-ATPase gene. In this work they showed that the coding 
sequence alone without the untranslated sequences shows induction by dexamethasone 
treatment. Our finding adds to this new paradigm of transcriptional regulation where the 











4.4    Effect of high glucose on HNF4A and its target genes     
                            
Since we observed that HNF4A is upregulated in diabetic nephropathy, we wanted to 
investigate the mechanism of upregulation of HNF4A and its targets.  It is known that 
there is constant hyperglycemia in diabetic patients. Hence we hypothesized that 
hyperglycemia has an effect on HNF4A promoter and HNF4A transcriptional activity. 
          For  this purpose we first tested HFN4A promoter under 5 mM and 25 mM d-
glucose. Fig 25 shows that for HNF4A promoter, there is ~50% increase in reporter 
activity with 25mM glucose compared to 5mM.. Hence our data shows that under high 
glucose conditions, promoter activity of HNF4A increases to express higher levels of 
HNF4A. This would explain the HNF4A upregulation in diabetic nephropathy. This 
increased promoter activity with high glucose maybe because of increased reactive 
oxygen species stress. It is known that ROS stress is increased in diabetes (Ha et al., 
2001). Guo et al(2006) has shown that ROS stress can increase HNF4A promoter activity. 
         This increase in reporter activity was observed for the pzlhiv reporter with four 
artificial HNF4A binding sites.  The 55% increase in reporter activity under 25mM 
glucose compared to 5 mM  in the presence of HNF4A(Fig 26).  This result shows us 
that HNF4A targets would be upregulated under high glucose conditions by increased 
transcriptional activity of HNF4A .  
           
            In fact ACADVL promoter activity is increased under high glucose 
concentrations in the presence of HNF4A(Fig 27). Thus ACADVL would be upregulated 
by two additive effects under high glucose conditions. Increase in levels of HNF4A due 
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to the effect on HNF4A promoter and the increased transactivation potential of HNF4A 
on ACADVL promoter. Although we tested only ACADVL in this work, we can 
postulate that other HNF4A targets would be upregulated in diabetes by similar mechani                  
 
 
      The increase in the transcriptional activity of HNF4A under high glucose conditions 
may be because of post translational modification of HNF4A. Previous work has shown 
that under redox inflammatory conditions (interleukin1 and h202 together) can mediate 
phosphorylation of HNF4A at Ser158, thus resulting in an increase in transcriptional 
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activity (Guo et al., 2006). Since high glucose is known to increase  reactive oxygen 
species(ROS) levels(Ha et al., 2001), HNF4A activity maybe increased by similar 
mechanisms . Furthermore we have shown that  ROS levels are increased in the case of 
diabetic nephropathy by using anti-nitrotyrosine staining which  is a marker of ROS 





















5   CONCLUSION AND FUTURE DIRECTIONS 
 
We have shown that the transcriptional factor Hepatocyte nuclear factor 4A (HNF4A) is 
upregulated in a range of kidney diseases. HNF4A is known to regulate genes involved in 
important metabolic and cellular processes. Hence we postulate that the HNF4A 
upregulation in the kidney diseases would lead to a cascade of molecular derangements 
which would aggravate the disease status.  
         We also showed that Acyl Coenzyme A dehydrogase very long chain (ACADVL) 
is a novel target gene of HNF4A.  This finding adds to the growing list of HNF4A target 
genes identified since its initial cloning. We identified a novel HNF4A response element 
distal to the translation start site in ACADVL gene. In order to fully characterize the 
HNF4A response element in ACADVL, we would like to carry out electromobility shift 
assay and chromatin immunoprecipitation. Recent discoveries have shown that distal 
promoters are important for a number of genes. The presence of a distal promoter in 
ACADVL was not known before. Furthermore, the transcriptional regulation of 
ACADVL was unexplored. We have shown that HNF4A is one of the key elements 
regulating ACADVL by binding to a distal response element. This finding paves the way 
to further studies of ACADVL transcriptional regulation. For example, how ACADVL 
expression is switched on during development is presently not known. In our future 
studies we intend to investigate whether HNF4A is the primary factor which switches on 
ACADVL during development. For this purpose we intend to chromatin 
immunoprecipitate HNF4A from the ACADVL sequence during different development 
stages. Furthermore, we plan to check for ACADVL expression in HNF4A knockout 
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mice.  We plan to do knockdown study of HNF4A in our future work. In the present 
study, we screened the kidney cell lines HEK293, MDCK and HK-2 cells for HNF4A 
expression. However none of these cell lines expressed HNF4A. Hence we could not 
knock down HNF4A.  
 
In our study ACADVL was seen to be upregulated in diabetic nephropathy together with 
HNF4A. It is highly possible that the increase in HNF4A levels lead to an increase in 
ACADVL expression. ACADVL is involved in the fatty acid oxidation. Hence the 
increase in expression would lead to an increase in fatty acid oxidation in diabetic 
nephropathy. Previous work has shown that there is increased fatty acid oxidation in 
certain kidney diseases. Our finding provides a molecular mechanism for this 
phenomenon. 
           It’s a well known fact that the diabetic condition eventually lead to dysregulation 
of lipid metabolism. The secondary defects in lipid metabolism leads to complications in 
diabetes. For example, arthrosclerosis is a very common in diabetic patients. My finding 
that hyperglycemia in diabetes leads to activation of HNF4A can provide the link 
between the diabetic condition and defects lipid metabolism. Other lipid metabolism 
genes might be deregulated via HNF4A in diabetes. For example the cholesterol synthetic 
enzyme HMG-CoA reductase is a target of HNF4A. HMG-CoA reductase could 
potentially be upregulated via HNF4A during hyperglycemia. This might be the reason 
why diabetes leads to hypercholesteremia. All these potential genes could not be 
investigated in the present work. For our future work we intend to investigate other 
potential target genes of HNF4A such as HMG-COA wich might be deregulated in a 
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similar manner, whereby hyperglycemia upregulates HMG-COA via HNF4A.  Our 
finding that ACADVL is upregulated by hyperglycemia via HNF4A provides a platform 
for these further studies. 
           We postulate that many metabolic and cellular processes are affected by the 
HNF4A upregulation in the kidney diseases studied. This offers the possibility of 
therapeutic intervention. If we suppress the expression of HNF4A, or inhibit its activity 
we may be able to reduce the severity of the disease. In our future work we would like to 
study the expression of Hepatocyte nuclear factor 4A(HNF4A) and its targets in a larger 
number of kidney disease cases. We would like to stain for other targets of HNF4A in 
order to study which other metabolic and cellular systems would be affected by HNF4A 
upregulation. We would also like to screen in vitro for potent inhibitors of HNF4A. Once 
we have identified an inhibitor, we would test the compound in animal models of kidney 
disease for therapeutic effect. Eventually if the animal models yield positive results, it 
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        APPENDIX 1 
 
 
GLUT2 expression during embryonic development . 
 
 
We wanted to investigate GLUT2 expression during embryonic development. HNF4A 
first appears in the kidney during embryonic day 14(e14).  Fluorescence staining shows 
that first appearance of GLUT2 coincides with HNF4A .  Panel A shows at lower 
magnification that few LTL (green) positive structures are present during e14 . A few of 
the LTL positive proximal tubules are seen to express GLUT2 (red).  Panel B shows a 
proximal tubule expressing GLUT2 at higher magnification. GLUT2 is expressed at the 





GLUT2 and LTL at e14 
            
 
                           A                                                                             B 
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        APPENDIX  2 
 




  Acute rejection case 1 56 M 0.5 
  Acute rejection case 2 48 M 168 
  Acute rejection case 3 50 F 39 
  Acute rejection case 4 57 F 0.5 
  Acute rejection case 5 24 F 10 
  Acute rejection case 6 24 F 12 
  IgA nephropathy case 1 55 M   
  IgA nephropathy case 2 33 F   
  IgA nephropathy case 3 39 M   
  IgA nephropathy case 4 40 F   
  IgA nephropathy case 5 20 M   
  Diabetic nephropathy  case 1 41 F   
  Diabetic nephropathy  case 2 59 M   
  Diabetic nephropathy  case 3 62 M   
  Diabetic nephropathy  case 4 68 M   
  Acute tubular injury     case 1 43 M   
  Acute tubular injury     case 2 17 F 0.25 
  Acute tubular injury     case 3 51 M 0 
  Acute tubular injury     case 4 53 M 0.5 
  Acute tubular injury     case 5 57 F 0 
  Acute tubular injury     case 6 55 M 0.25 
  Acute tubular injury     case 7 37 F 0.5 
  Acute Tubular Injury    case8 58 F 0.25 
  IFTA (CAN)                 case 1 43 F 36 
  IFTA (CAN)                 case 2 38 M 38 
  IFTA (CAN)                 case 3 50 F 31 
  IFTA (CAN)                 case 4 30 F 2 
  IFTA (CAN)                 case 5 26 M   
  Minimal change disease   case 1 16 M   
  Minimal change disease   case 2 23 F   
  Minimal change disease   case 3 23 M   
  Minimal change disease   case 4 28 M   
  AIN                                case 1 64 M   
  AIN                                case 2 41 F   
  
Ischaemic/hypertensive nephropathy   49 F    
 Table 1 : Case histories- Patient diagnosis, age, gender and months post transplant  
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Fig 31:Automated scoring of stained nuclei 
Percentage of  Strong, Moderate, Weak, No staining nuclei is shown for each disease together with 
control. Comparison with manual scoring shown in the results section shows that there is no 
significant difference. The same conclusions were drawn as seen from the manual scoring. 
More strongly stained nuclei were seen for Diabetic nephropathy, Minimal change, Acute tubular 
injury, Acute rejection and IgA nephropathy. No significant difference was seen for IFTA staining 
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Representative image  from control 1                Representative image from control 2     
                
                                                               
Representative image  from control 3                Representative image from control 4 
 
 
Fig 32    Representative images from the four control samples stained for HNF4A 
All sections have been counterstained with hematoxyllin. Images have been captured  with 
















Fig 33 : Semiquantitative RT-PCR results. Lane 1 is the 1kb ladder. Lane 2 is GAPDH RT-PCR of 
control mice kidney, Lane 3 is GAPDH RT-PCR of diabetic mouse kidney. Lane 4 is ACADVL 
RT-PCR of control mice kidney. Lane 5 is ACADVL RT-PCR of diabetic kidney. 
Product size of GAPDH and ACADVL is 1.3 Kb(primers were selected to give the same product 
size. 
 
 
 
 
 
 
 
 
 
 
 
